Emerging technologies that overcome biological barriers for therapeutic protein delivery

被引:10
作者
Daugherty, AL [1 ]
Mrsny, RJ [1 ]
机构
[1] Genentech Inc, Dept Pharmaceut Res & Dev, San Francisco, CA 94080 USA
关键词
biological barrier; blood-brain barrier; drug delivery; oral; protein delivery; pulmonary; transdermal;
D O I
10.1517/eobt.3.7.1071.21281
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the past decade, genomic research and the nascent field of proteomics have exponentially increased the number of potential protein therapeutic molecules for treating medical needs that were previously unmet. To realise the full clinical potential of many of the novel protein drug entities arising from these intense research efforts, emerging protein delivery technologies may be required. Advanced delivery technologies may offer the ability to overcome biochemical and anatomical barriers to protein drug transport, without incurring adverse events, to deliver the agent(s) at a certain desired rate and duration, to protect therapeutic macromolecules from in situ or systemic degradation, as well as increase their therapeutic index by targeting the drug action to a specific site. This review will cover a myriad of novel and emerging technologies that are directed at bypassing biological barriers and that have shown promise in advancing the therapeutic potential of protein drugs.
引用
收藏
页码:1071 / 1081
页数:11
相关论文
共 96 条
[1]   Recombinant proteins for neurodegenerative diseases: the delivery issue [J].
Aebischer, P ;
Ridet, JL .
TRENDS IN NEUROSCIENCES, 2001, 24 (09) :533-540
[2]   CLINICAL-SIGNIFICANCE OF RECOMBINANT INTERFERON-ALPHA(2) NEUTRALIZING ANTIBODIES IN HEPATITIS PATIENTS [J].
ANTONELLI, G ;
GIANNELLI, G ;
PISTELLO, M ;
MAGGI, F ;
VATTERONI, L ;
CURRENTI, M ;
DELVECCHIO, S ;
ROFFI, L ;
PASTORE, G ;
DIANZANI, F .
JOURNAL OF INTERFERON RESEARCH, 1994, 14 (04) :211-213
[3]   Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues [J].
Ballesteros, M ;
Leung, KC ;
Ross, RJM ;
Iismaa, TP ;
Ho, KKY .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) :2865-2871
[4]   Novel mechanisms and devices to enable successful transdermal drug delivery [J].
Barry, BW .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) :101-114
[5]   Is transdermal drug delivery research still important today? [J].
Barry, BW .
DRUG DISCOVERY TODAY, 2001, 6 (19) :967-971
[6]   Delivery of peptides and proteins through the blood-brain barrier (Reprinted from Advanced Drug Delivery Reviews, vol 10, pg 205-245, 1993) [J].
Bickel, U ;
Yoshikawa, T ;
Pardridge, WM .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :247-279
[7]   Plasma membrane components of adherens junctions (Review) [J].
Blaschuk, OW ;
Rowlands, TM .
MOLECULAR MEMBRANE BIOLOGY, 2002, 19 (02) :75-80
[8]   Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response [J].
Bryan, SA ;
O'Connor, BJ ;
Matti, S ;
Leckie, MJ ;
Kanabar, V ;
Khan, J ;
Warrington, SJ ;
Renzetti, L ;
Rames, A ;
Bock, JA ;
Boyce, MJ ;
Hansel, TT ;
Holgate, ST ;
Barnes, PJ .
LANCET, 2000, 356 (9248) :2149-2153
[9]   Nanosphere based oral insulin delivery [J].
Carino, GP ;
Jacob, JS ;
Mathiowitz, E .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :261-269
[10]   Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C [J].
Carreño, V ;
Martín, J ;
Pardo, M ;
Brotons, A ;
Anchía, P ;
Navas, S ;
Fernández, M ;
Arocena, C ;
Quiroga, JA .
CYTOKINE, 2000, 12 (02) :165-170